Surgical treatment in acromegaly: experience in Córdoba
DOI:
https://doi.org/10.31053/1853.0605.v77.n4.29073Keywords:
acromegaly, neurosurgery, postoperative complications, remission inductionAbstract
Introduction: Acromegaly prevalence is 35-70 / million. Transsphenoidal surgery is the first-line treatment, with a remission rate of 80% for microadenomas and 50% for macroadenomas. Our aim was to evaluate the surgical results in Córdoba and determine predictive remission factors due to the lack of records. Methods: Retrospective-descriptive study of patients with surgery as the first therapeutic line. Remission criteria: IGF1 normalization for age/sex, with GH ≤1.0 g/L. Test X2 and Fisher's exact test with p<0.05. Results: 38 patients were included: 61% women and 39% men; Average age 45 years. Most frequent chief complaint: headache and acral growth (26%), visual disturbances (20%). Macroadenomas were the 84% of the tumors. Of 37 patients, 54% underwent microscopic surgery, 38% endoscopic and 8% transcranial. The 29% of patients showed post-operative complications and diabetes insipidus was the most frequent (10%). The percentage of them was: 33% transcranial surgery, 29% endoscopic and 25% microscopic (p = 0.557). The biochemical remission at 6 months was 34% and at 12 months 55% (p= 0.0001). No significant differences between the endoscopic and microscopic approach (p = 0.071). Of 36 patients, 31% showed complete tumor resection. The subjective clinical improvement was 88%. There weren´t predictive remission factors with significant differences. Conclusion: The surgical biochemical remission was similar to the bibliography. We didn´t find predictive remission factors but a larger number of patients could modify these results.
Downloads
References
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematicreview. Cancer. 2004;101:613–619.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross sectional study in the province of Liege, Belgium. J ClinEndocrinolMetab. 2006;12:12–20.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).ClinEndocrinol. 2010;72(3):377–382. doi: 10.1111/j.1365-2265.2009.03667.x
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16: 294-302.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89–95. 10.1530/EJE-08-0267.
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J ClinEndocrinolMetab. 2008; 61–67. (10.1210/jc.2007-1191)
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: anendocrinesocietyclinicalpracticeguideline. J ClinEndocrinolMetab. 2014;99:3933-3951.
Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J ClinEndocrinolMetab. 2013;98:3190-3198.
Hardy J, Vezina JL. Transsphenoidal neurosurgery of intracranialneoplasm. AdvNeurol 1976;15:261–273.
Knosp E., Steiner E., Kitz K., Matula C. Pituitary adenomas with invasion of the cavernous sinus space. Neurosurgery. 1993;33(4):610–618. doi: 10.1227/00006123-199310000-00008.
Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2(1):29–41
Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16(3):181e7.
Vilar L., Vilar C. F., Lyra R., Lyra R., Naves L. A. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22–32. doi: 10.1007/s11102-016-0772-8.
Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, et al. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine. 2018;63:120–129. doi: 10.1007/s12020-018-1764-4.
Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J ClinEndocrinolMetab. 2014; 99:4438–46. 10.1210/jc.2014-2670.
Antunes, X., Ventura, N., Camilo, G.B. etal.Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 2018; 60:415–422. https://doi.org/10.1007/s12020-018-1590-8.
Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 2012; 77:72–78. doi: 10.1111/j.1365-2265.2011.04286.x.
Berker M, Hazer DB, Yücel T, Gürlek A, Cila A, Aldur M, et al. Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature. Pituitary. 2012;15(3):288-300. doi:10.1007/s11102-011-0368-2.
Mortini P, Barzaghi LR, Albano L, Panni P, Losa M. Microsurgical therapy of pituitary adenomas. Endocrine. 2018; 59:72–81.
Chen C-J, Ironside N, Pomeraniec IJ, Chivukula S, Buell TJ, Ding D, Taylor DG, Dallapiazza RF, Lee C-C, Bergsneider M. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. ActaNeurochirurgica 2017. 159 2193–2207 doi:10.1007/s00701-017-3318-6.
Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, et al. Preoperative Octreotide Treatment of Acromegaly Study Group Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J ClinEndocrinolMetab. 2008;93:2984–2990. doi: 10.1210/jc.2008-0315.
Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, et al. Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.JClinEndocrinolMetab. 2020 Mar 1;105(3). pii: dgz187. doi: 10.1210/clinem/dgz187.
Asha MJ, Takami H, Velasquez C, Oswari S, Almeida J, Zadeh G, Gentili F. Long-term outcomes of transsphenoidal surgery for management of growth hormone–secreting adenomas: single-center results. J Neurosurg. 2019 Oct 11:1-11. doi: 10.3171/2019.6.JNS191187. [Epub ahead of print].
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
